Collectively, these data indicate that losartan can (i) normalise dysfunctional vessels and improve perfusion in tumours where stromal compression is dominant, (ii) stabilise microvascular architecture in tumours with pericyte‐related defects and (iii) act synergistically with targeted agents (e.g., VEGF inhibitors, multi‐kinase inhibitors) to overcome resistance—while the relative contribution of each mechanism varies by tumour histology and microenvironmental context [13, 42, 62, 64, 80, 81, 84, 85]. The gene discussed is VEGFA; the disease is neoplasm.